AdaptHealth reported third-quarter 2026 net revenue of $745.6 million, up 10.9% from a year earlier, but a $184.8 million pre-tax goodwill write-down produced a net loss. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance but lowered its free cash flow guidance, and it cleared the Hart-Scott-Rodino waiting period for the pending $235.0 million sale of its Diabetes Health business.
Q3 net revenue $745.6 million vs. $672.4 million; organic revenue growth of 12.8%
Q3 Adjusted EBITDA $141.9 million vs. $146.1 million, down 2.9%
2026 guidance: revenue raised to $2.88-$2.90 billion; Adjusted EBITDA raised to $510-$525 million; free cash flow cut to $50-$75 million from $80-$120 million
Diabetes Health sale for $235.0 million in cash expected to close in early 2027
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.